

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: KLIEWER et al.
Serial No.: 09/276,935
Filed: March 26, 1999
Title: *An Orphan Nuclear Receptor*

Group Art Unit: 1646
Examiner: Michael D. Pak

REVOCATION OF PRIOR POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE
INTEREST, APPOINTMENT OF NEW POWER OF ATTORNEY, AND CHANGE OF
CORRESPONDENCE ADDRESS

Commissioner for Patents
Washington, D.C. 20231

Sir:

The assignee of record of the entire interest of the identified

☒ application
☐ patent

REVOCATION OF PRIOR POWERS OF ATTORNEY

hereby revokes all previous powers of attorney and

NEW POWER OF ATTORNEY AND CHANGE OF ADDRESS

appoints the practioners at Customer Number 23347 as our attorney(s) or agent(s) to prosecute and
transact all business in the Patent and Trademark Office connected therewith.

CUSTOMER NUMBER BAR CODE LABEL:



Please direct all future written correspondence and telephone calls to the above mentioned
Customer Number.

CUSTOMER NUMBER BAR CODE LABEL:



#35
By
4/10/03
Already done

The United States Patent and Trademark Office recorded the assignment for this application to
GLAXO WELLCOME INC. on June 28, 1999 Reel/Frame: 010053/0547.
Or

A copy of the Assignment is attached.


A copy of Certificate 373(b) is also attached.

Respectfully submitted,

SmithKline Beecham Corporation

Date: MARCH 7, 2003
GlaxoSmithKline
Intellectual Property Department

Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Telephone No.: (919) 483-8247
Facsimile No.: (919) 483-7988


BY: David J. Lew
Title: Assistant Secretary,
Corporate Intellectual Property
Registration No.: 27,655

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Applicant: Steven A. KLIEWER et al.

Patent Application No.: 09/276,935 Filed: March 26, 1999

For: AN ORPHAN NUCLEAR RECEPTOR

Glaxo Wellcome Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 010053, Frame 0547, or for which a copy thereof is attached.

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or which a copy thereof is attached.

☒ Additional documents in the chain of title are listed on a supplemental sheet.

Articles of Merger of SmithKline Beecham Corporation showing merged entity is Glaxo Wellcome Inc., effective March 31, 2001.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature: David J. Levy Date: MARCH 7, 2003

Name: David J. Levy

Title: V.P. Intellectual Property Counsel, Assistant Secretary,
SmithKline Beecham Corporation
Address: GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
Telephone No.: (919) 483-2252
Facsimile No.: (919) 483-7988

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE

APRIL 05, 2001

TO ALL WHOM THESE PRESENTS SHALL COME, GREETING:

SMITHKLINE BEECHAM CORPORATION

I, Kim Pizzingrilli, Secretary of the Commonwealth of Pennsylvania do hereby certify that the foregoing and annexed is a true and correct photocopy of Articles of Merger restating the Articles of Incorporation in their entirety which appear of record in this department



IN TESTIMONY WHEREOF, I have hereunto set my hand and caused the Seal of the Secretary's Office to be affixed, the day and year above written.

Kim Pizzingrilli

Secretary of the Commonwealth

DPQS

MAR 7 2003 4:13PM

GLAXO WELLCOME

NO. 7780 P. 8

RETURN TO CSC

MAR 30 2001

Filing Number

Filed with the Department of State on

Filing Number

333095

Secretary of the Commonwealth

SK

ARTICLES OF MERGER-DOMESTIC BUSINESS CORPORATION

DSCA13-1726 (Rev. 90)

In compliance with the requirements of 15 Pa.C.S. § 1926 (relating to articles of merger or consolidation), the undersigned business corporations, desiring to effect a merger, hereby state that:

the name of the corporation surviving the merger is: SmithKline Beecham Corporation

(Check and complete one of the following):

X The surviving corporation is a domestic business corporation and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of the Department):

(a) One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 Phila.
Number and Street City State Zip County

(b) c/o: _____
Name of Commercial Registered Office Provider County

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a qualified foreign business corporation incorporated under the laws of _____ and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of the Department):

(a) _____
Number and Street City State Zip County

(b) c/o: _____
Name of Commercial Registered Office Provider County

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a nonqualified foreign business corporation incorporated under the laws of _____ and the address of its principal office under the laws of such domiciliary jurisdiction is:

Number and Street City State Zip

3. The name and the address of the registered office in this Commonwealth or name of its commercial registered office provider and the county of venue of each other domestic business corporation and qualified foreign business corporation which is a party to the plan of merger are as follows:

Name of Corporation	Address of Registered Office or Name of Commercial Registered Office Provider	County
Glaxo Wellcome Inc.	CI Corporation System	Philadelphia

THIS IS A TRUE COPY OF
THE ORIGINAL SIGNED
DOCUMENT FILED WITH
THE DEPARTMENT OF STATE.

03CB:15-1926 (Rev 90)-2

4. (Check, and if appropriate complete, one of the following):

 The plan of merger shall be effective upon filing these Articles of Merger in the Department of State.

 x The plan of merger shall be effective on March 31, 2001 at 11:30 p.m.
Date Hour

5. The manner in which the plan of merger was adopted by each domestic corporation is as follows:

Name of Corporation	Manner of Adoption
<u>SmithKline Beecham Corporation</u>	<u>Adopted by the directors and shareholders pursuant to 15 Pa.C.S. § 1924(a).</u>

6. (Strike out this paragraph if no foreign corporation is a party to the merger). The plan was authorized, adopted or approved, as the case may be, by the foreign business corporation (or each of the foreign business corporations) party to the plan in accordance with the laws of the jurisdiction in which it is incorporated.

7. (Check, and if appropriate complete, one of the following):

 x The plan of merger is set forth in full in Exhibit A attached hereto and made a part hereof.

 Pursuant to 15 Pa.C.S. § 1901 (relating to omission of certain provisions from filed plans) the provisions, if any, of the plan of merger that amend or constitute the operative Articles of Incorporation of the surviving corporation as in effect subsequent to the effective date of the plan are set forth in full in Exhibit A attached hereto and made a part hereof. The full text of the plan of merger is on file at the principal place of business of the surviving corporation, the address of which is:

Number and Street	City	State	Zip	County
-------------------	------	-------	-----	--------

IN TESTIMONY WHEREOF, the undersigned corporation or each undersigned corporation has caused these Articles of Merger to be signed by a duly authorized officer thereof this day of March, 2001.

SMITHKLINE BEECHAM CORPORATION

(Name of Corporation)

BY: Donald Y. Parman

(Signature)

TITLE: Donald Y. Parman, SecretaryGLAXO WELLCOME INC.

(Name of Corporation)

BY: Paul A. Holcombe, Jr.

(Signature)

TITLE: Paul A. Holcombe, Jr., Secretary

POWER OF ATTORNEY

BY THIS POWER OF ATTORNEY given this 16th day of May, Two Thousand and One, **SMITHKLINE BEECHAM CORPORATION**, a Company duly incorporated in Pennsylvania under registered no 23-1099050 and having its Registered Office at One Franklin Plaza, Philadelphia, Pennsylvania 19101, United States of America, (hereinafter called "the Company") appoints any one Director, the Secretary, or any Assistant Secretary from time to time, and **WILLIAM T KING** and **STEPHEN VENETIANER**, both of GlaxoSmithKline, and located at 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, and, **CHARLES E DADSWELL**, **ROBERT H BRINK**, and **FRANK P GRASSLER**, all of GlaxoSmithKline, and located at Five Moore Drive, Research Triangle Park, North Carolina 27709, United States of America, and **DAVID ROBERTS**, **PETER JOHN GIDDINGS**, **ALAN SINCLAIR COX** and **JAMES ALAN THOMAS**, all of GlaxoSmithKline, and located at Two New Horizons Court, Brentford, Middlesex TW8 9EP, England, and **DAVID MARTIN WATERS** and **HUGH BAINFORDE DAWSON**, both of GlaxoSmithKline, and located at New Frontier's Science Park, Essex, England, and **WENDY ANNE FILLER**, and **MICHAEL JOHN STOTT**, both of GlaxoSmithKline, and located at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB60NN, England jointly, and each of them severally (hereinafter called "the Attorney") to be the true and lawful Agent and Attorney of the Company on behalf of and in the name of the Company or otherwise to do, perform, exercise and execute or concur with any other person or persons in doing, performing, exercising and executing in any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things, that is to say:

1. To make application or cause application to be made for the grant to the Company and the proper registration in the name of the Company of any letters patent, trade mark, trade name, registered design or other intellectual property right whatever and to take all steps necessary for the same to be prosecuted and maintained.
2. As the act and deed of the Company to sign, seal and deliver and execute all or any assignments or assurances to the Company of any letters patent, registered trade mark, trade name, registered design or other intellectual property right or any application therefor for the purpose of fully and effectually vesting and transferring the same into the name of the Company insofar as such documents can be executed without the company's seal being affixed thereto.
3. As the act and deed for the Company to sign, seal, deliver and execute all or any assignments, assurances, licences or sub-licences from the Company of or under any letters patent, registered trade mark, trade name, registered design or other intellectual property right or any application therefor for the purpose of fully and effectually vesting, transferring or granting the same into the name of any person or company (whether in the United States of America or elsewhere) insofar as such documents can be executed without the Company's Seal being affixed thereto.
4. To sign and execute all documents relating to applications for letters patent, registered trade marks, trade names, registered designs or other intellectual property rights or the renewal thereof or to assignments or assurances of the same or applications therefor.

P. 1/2

JUN 28 02 10:50AM GLAXO WELLCOME

5. To act in regard to all official communications which may now or hereafter be addressed to the Company or to the Attorney relating to applications for letters patent, registered trade marks, trade names, registered designs or other intellectual property right or the renewal thereof in such manner that the Attorney may be recognised as the authorised Agent of the Company in all proceedings incidental thereto.
6. For, or in connection with any letters patent, registered trade mark, trade name, registered design or other intellectual property right or application therefor to sign, seal, deliver and execute any Power of Attorney or other deed or document:
 - a) authorising any firm or patent agents or trade mark agents in the United States of America to act on behalf of the Company;
 - b) authorising any person, persons, firm or company practising as patent agents or trade mark agents or otherwise entitled to act as agents for all matters relating to letters patent, trade marks, trade names, registered designs or other intellectual property rights outside the United States of America to act on behalf of the Company, with powers of substitution.
7. To initiate or cause to be initiated or to appear as defendant, complainee, interpleader or enjoined third party in any Patent Office or Registry or any Trade Mark Registry or Court or other agency or government department or otherwise responsible for the registration or protection of letters patent, trade marks, trade names, registered designs or other intellectual property rights in respect of any proceedings or application whatsoever relating to any proprietary rights whether in the name of the Company or not and to cause such proceedings or applications to be maintained or withdrawn.
8. This Power of Attorney shall expire on December 31, 2002, unless revoked prior to that date by the grantor.

AND THE COMPANY HEREBY RATIFIES AND CONFIRMS and agrees to ratify and confirm all and whatsoever the Attorney or any person, persons, firm or company appointed by him shall lawfully do or have done or cause to be done by virtue of the authority herein contained, including in such ratification and confirmation all and whatsoever the hereby appointed Attorney may already have done in purported exercise of the authorities presently vested in him.

AND THE COMPANY HEREBY DECLARES that this Power of Attorney is in substitution for and shall revoke all previous Powers of Attorney granted by the Company to the Attorney to do any of the acts and things hereby authorised to be done and remaining unrevoked PROVIDED that nothing herein contained shall affect the validity of any act or thing done by the Attorney by virtue thereof before the execution of this Power.

IN WITNESS WHEREOF the Company has caused its Common Seal to be hereunto affixed the day and year first before written.

THE COMMON SEAL OF
SmithKline Beecham Corporation
was hereunto affixed in the presence of:-

Donald F. Parman
Donald F. Parman, Secretary

P. 2/2

JUN 20 01 10:51AM GLAXO WELLCOME

FAX

GlaxoSmithKline

To Examiner Michael D. Pak, Group 1646**Company** USPTO**Fax** 703-872-9306**From** Marjorie J. Pfeiffer**Tel** 1-919-483-9038; Facsimile: 1-919-483-7988**E-mail** Mjp14849@gsk.com**Date** **Pages including cover** 14**Subject** Revocation of POA, New POA, and Correspondence**Address**

GlaxoSmithKline

PO Box 13398

Five Moore Drive

Research Triangle Park

North Carolina 27709

Tel: 919 483 2100

www.gsk.com

FAX RECEIVED

MAR 10 2003

GROUP 1600**OFFICIAL**

Re: Application of KIEWER et al.
U.S. Serial No.: 08/276,935; Filed: March 26, 1999
Title: *An Orphan Nuclear Receptor*
Attorney Docket No. PU3474US2

Attached:

1. Certificate of Transmission (37 CFR 1.8(a))
2. Transmittal Form
3. Revocation of Prior Power of Attorney by Assignee, Appointment of New Power of Attorney, and Change of Correspondence Address
4. Certificate under 37 CFR 3.73(b)
5. Power of Attorney (SmithKline Beecham Corporation)
6. Articles of Merger

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No. PU3474US2
Applicant(s): KLIEWER et al.			
Serial No. 09/276,935	Filing Date March 26, 1999	Examiner Michael D. Pak	Group Art Unit 1646
Invention: AN ORPHAN NUCLEAR RECEPTOR			
<p>I hereby certify that this <u>Revocation of Prior Power of Attorney, New Power of Attorney and accompanying</u> <small>(Identify type of correspondence)</small></p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u>)</p> <p>on <u>March 7, 2003</u> <small>(Date)</small></p> <p style="text-align: right;"><u>Marjorie J. Pfeiffer</u> <small>(Typed or Printed Name of Person Signing Certificate)</small></p> <p style="text-align: right;"><u>Marjorie J. Pfeiffer</u> <small>(Signature)</small></p> <p style="text-align: center;">Note: Each paper must have its own certificate of mailing.</p>			

Please type a plus sign (+) inside this box → ☐

PTO/38/21 (08-00)


Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application	09/276,935
	Filing Date	March 26, 1999
	First Named	Steven A. KIEWER
	Group Art Unit	1646
	Examiner Name	Michael D. Pak
Total Number of Pages in This Submission	Attorney Docket Number	FU3474US2

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Certificate under 37 CFR 3.73(b) 2. Articles of Merger 3. Power of Attorney (Smithkline Beecham Corporation)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michael M. Cenger, Reg. 43,562
Signature	
Date	March 7, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: _____

Typed or printed name	_____
Signature	_____
Date	_____

⊕ Burden JUDR Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.